View Latest Issue
Gout affects 1% to 2% of adults in Western countries and 2.5% of adults in the United Kingdom. Compared with the general population, patients with gout have increased cardiovascular morbidity and mortality, and researchers largely attribute this increased risk to urate levels.
Tampa, FL—There have been considerable advances in the treatment of patients with rheumatoid arthritis (RA), including new biologic agents. Although research supports the safety and efficacy of these medications, the effectiveness of biologics is often limited by patient adherence.
Paris, France—Three biomarkers have been identified that may be used to determine disease severity in osteo­arthritis (OA), according to data presented at the 2014 European League Against Rheumatism (EULAR) Congress. The miRNAs—miR 454, miR 885-5p, and miR let-7e—may predict the development of severe OA in patients with early disease.
Tampa, FL—Current disease assessment measures for rheumatoid arthritis (RA) are not optimal and have several limitations, including subjective and variable assessment of disease activity, limited predictive ability to capture structural joint damage, and presence of confounding comorbidities.
Paris, France—Biologics are a welcome advance for the treatment of patients with rheumatoid arthritis. They appear to be safe in adults, but there is always heightened concern when it comes to the effects of immunosuppressants and biologics in children.
Tampa, FL—Post-hoc analyses of the phase 3 trials, ORAL Standard and ORAL Step, revealed that tofacitinib––a novel oral Janus kinase inhibitor––and adalimumab led to lower monthly medical expenditures (MMEs) compared with placebo in patients with moderate-to-severe rheumatoid arthritis (RA) who did not respond to either methotrexate or tumor necrosis factor (TNF) inhibitors, according to investigators Regina Rendas-Baum, MS, scientist at QualityMetric, and colleagues.
In 2013, the National Vaccine Advisory Committee (NVAC) updated its Standards for Adult Immunization Practice.1 The new standards, recognizing the dismal rate of adult vaccination in the United States, emphasized the role of all providers to assess immunization status and recommend needed vaccines.
Toronto, ON—The results of a study on new-onset psoriatic arthritis (PsA) underline the importance of attention to warning signs in order to achieve early referral of patients to rheumatologists. The study showed that the risk for PsA, which is a relatively common condition, is highest in individuals with a higher Psoriasis Area and Severity Index (PASI) score, nail involvement, and a higher body mass index (BMI).
Paris, France—Long-term safety data of tofacitinib were reassuring, demonstrating no new safety concerns in patients with rheumatoid arthritis (RA) exposed to the drug for as long as 4 years. The pattern of adverse events remained stable over time, according to an integrated safety analysis presented at the 2014 European League Against Rheumatism Congress.
Paris, France—A study presented at the 2014 European League Against Rheumatism (EULAR) Congress reports that a sizable proportion of selected patients with lupus can stop therapy without triggering new disease flares for up to 5 years.
Page 2 of 3
Results 11 - 20 of 23
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology